Telesis Therapeutics is developing compounds that disrupt thiol homeostasis in the glucose-deprived conditions of the tumor microenvironment. Their lead compound TTL-315 is initially aimed at pancreatic cancer.
Telesis Therapeutics, LLC is a Philadelphia, PA based early stage Biopharmaceutical Company. We develop and commercialize breakthrough scientific discoveries acquired from research institutions and prepare these assets for clinical translation. Our mission is to identify oncology drug discoveries, and shepherd these discoveries into therapies to treat patients in need of new, more effective, therapeutic options.